mucosal wound healing and the response to inflammatory stimuli in the adult gastrointestinal tract.[3] As these are vital homeostatic roles, it seems unlikely that the periglandular fibroblast sheath is only generated in abnormal metaplastic tissue. We immunostained for ISEMF in paraffin embedded normal mouse and human stomach specimens. To identify ISEMF, we stained for α-SMA in three mouse gastric specimens, and α-SMA and vimentin in six sets of human gastric biopsies. Sections for vimentin staining underwent 10 minutes of microwave treatment in citrate buffer for antigen retrieval. Immunostaining was completed using the same antibodies and methods described in detail by Direkze and colleagues.[5] Antibody binding was detected by 1,3-diaminobenzidine (DAB; Sigma, St Louis, Missouri, USA). ISEMF were identified on the basis of their morphology and positive immunoreactivity for α-SMA in mouse tissue, and α-SMA and vimentin in human tissue. They were clearly and consistently seen surrounding the stomach glands in normal mouse and human stomach sections, both in the en face and cross sectional plane (see fig 1). There was little variation in staining intensity from sample to sample in the three mouse and six human subjects studied.

ISEMF are involved in the response to damage or disease in the stomach. After epithelial injury, ISEMF contraction limits the exposed area of the wound while secreted growth factors such as transforming growth factors α and β, epidermal growth factor, and fibroblast growth factor promote epithelial cell migration and proliferation.[3] In intestinal-type gastric cancer, myofibroblasts appear not only at the edge of the tumour, contributing to a desmoplastic reaction, but also within the tumour stroma.[4] The presence of increased inter-tubular reticulin, the histological hallmark of increased extracellular matrix deposition, is regarded as among the first signs of chronic atrophic gastritis, and likely to be caused by elevated numbers or activity of ISEMF. The source of these cells is very interesting—it is more likely that these cells are recruited from circulating precursor cells rather than being generated by metaplastic mucosa. Direkze *et al* have shown a large contribution of bone marrow donor derived myofibroblasts, making up to 64% of the periglandular fibroblast sheath in mouse stomach after total body irradiation and bone marrow transplant,[5] and Nakayama *et al* hypothesise that engraftment is responsible for myofibroblast presence in tumours.[4] The mechanisms initiating this engraftment are unclear but it may relate to the release of growth factors, such as transforming growth factor β,[6] released from inflammatory cells and the existing periglandular fibroblast sheath in response to gastritis induced damage.

We conclude that the periglandular myofibroblast sheath in normal stomach is very much a reality and likely to be pivotal in modulating epithelial cell behaviour.

S J Leedham, M Brittan, S L Preston, S A C McDonald, N A Wright
Histopathology Unit, Cancer Research UK, London, UK

Correspondence to: Dr S Leedham, Histopathology Unit, Cancer Research UK, 44 Lincoln's Inn Fields, London WC2A 3PX, UK; simon.leedham@cancer.org.uk

Grant support was provided by the Medical Research Council Clinical Research Fellowship.

Conflict of interest: None declared.

References

1 **Mutoh H**, Sakurai S, Satoh K, *et al*. Pericryptal fibroblast sheath in intestinal metaplasia and gastric carcinoma. *Gut* 2005;**54**:33–9.
2 **Spradling A**, Drummond-Barbosa D, Kai T. Stem cells find their niche. *Nature* 2001;**414**:98–104.
3 **Powell DW**, Mifflin RC, Valentich JD, *et al*. Myofibroblasts. I. Paracrine cells important in health and disease. *Am J Physiol* 1999;**277**(1 Pt 1):C1–9.
4 **Nakayama H**, Enzan H, Miyazaki E, *et al*. Alpha smooth muscle actin positive stromal cells in gastric carcinoma. *J Clin Pathol* 2002;**55**:741–4.
5 **Direkze NC**, Forbes SJ, Brittan M, *et al*. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. *Stem Cells* 2003;**21**:514–20.
6 **Abe R**, Donnelly SC, Peng T, *et al*. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. *J Immunol* 2001;**166**:7556–62.

Anti-*saccharomyces cerevisiae* antibodies (ASCA) in coeliac disease

We read with great interest the paper by Israeli and colleagues (*Gut* 2005;**54**:1232–6) assessing the presence of anti-*Saccharomyces cerevisiae* antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) before the occurrence of overt clinical manifestations in patients with Crohn's disease (CD) and ulcerative colitis (UC). They found that ASCA were present in 31% of CD patients before clinical diagnosis (but not in UC patients or controls), and that pANCA were detectable in two (25%) of eight UC patients before clinical manifestations but not in 24 matched controls. These observations led the authors to conclude that ASCA and pANCA may predict the development of inflammatory bowel disease long before its clinical onset.

We have recently published our experience on the prevalence and behaviour of ASCA and pANCA in adult and paediatric coeliac disease patients.[1] Sixty two (59%) of 105 coeliac patients had IgA and/or IgG ASCA (Quanta Lite ASCA IgG and IgA assay; Inova Diagnostics, San Diego, California, USA) at diagnosis while only one patient (0.9%) had pANCA. No significant correlation was found between ASCA positivity and severity of small intestinal mucosal damage. Moreover, after a gluten free diet (mean 14.4 (2.7) months), 93% of revaluated coeliac patients lost IgA ASCA whereas 83% maintained IgG ASCA reactivity.

Interestingly, seven (six women; median age 26 (range 18–33) years) of the 62 coeliac patients with IgA and/or IgG ASCA were diagnosed before developing any clinical symptoms as they were screened as first degree relatives of coeliac patients. All had antitissue transglutaminase antibodies (tTG), antiendomysial antibodies (EmA), the HLA DQ2/DQ8 haplotype, and a histological picture on small intestinal biopsy showing an increased number of intraepithelial lymphocytes in five and mild villous flattening in two (grade 1 and grade 3a, respectively, according to Marsh's classification modified by Oberhuber).

In this type of patient, known as having ''potential'' and ''silent'' coeliac disease, respectively, positivity for the serological markers (EmA and tTG) together with the typical HLA predisposing genotype (DQ2 or DQ8) allows accidental diagnosis of gluten enteropathy when clinical manifestations are still lacking.[2 3]

Our observation indicates that in asymptomatic patients, ASCA positivity is not only predictive of CD but may also be associated with ''potential/silent'' coeliac disease. Increased permeability in the small bowel of coeliac patients seems to be an early event, preceding the development of more severe mucosal damage.[4 5] Similar to asymptomatic CD patients, the altered permeability of the small bowel towards yeast antigens could account for the occurrence of ASCA from a very early stage of the disease in asymptomatic coeliac patients, as suggested by our five coeliac patients with minimally abnormal mucosal architecture. The ''altered permeability'' hypothesis should be investigated further to explain the frequent detection of ASCA in other autoimmune disorders, such as primary biliary cirrhosis and primary sclerosing cholangitis.[6]

A Granito, L Muratori, P Muratori, M Guidi, M Lenzi, F B Bianchi, U Volta
Department of Internal Medicine, Cardioangiology, Hepatology, Alma Mater Studiorum-University of Bologna, Bologna, Italy

Correspondence to: Dr A Granito, Department of Internal Medicine, Cardioangiology, Hepatology, Alma Mater Studiorum-University of Bologna, Policlinico S Orsola-Malpighi, via Massarenti 9, 40138 Bologna, Italy; gralex@libero.it

Conflict of interest: None declared.

References

1 **Granito A**, Zauli D, Muratori P, *et al*. Anti-Saccharomyces cerevisiae and perinuclear antineutrophil cytoplasmic antibodies in coeliac disease before and after gluten free diet. *Aliment Pharmacol Ther* 2005;**21**:881–7.
2 **Fasano A**, Catassi C. Current approaches to diagnosis and treatment of coeliac disease: an evolving spectrum. *Gastroenerology* 2001;**120**:636–51.
3 **Vasquez H**, Cabanne A, Sugai E, *et al*. Serological markers identify histologically latent coeliac disease among first-degree relatives. *Eur J Gastroenterol Hepatol* 1996;**8**:15–21.
4 **van Elburg RM**, Uil JJ, Mulder CJ, *et al*. Intestinal permeability in patients with coeliac disease and relatives of patients with coeliac disease. *Gut* 1993;**34**:354–7.
5 **Clemente MG**, De Virgiliis S, Kang JS, *et al*. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. *Gut* 2003;**52**:218–23.
6 **Muratori P**, Muratori L, Guidi M, *et al*. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. *Clin Exp Immunol* 2003;**132**:473–6.